{"nctId":"NCT03412890","briefTitle":"LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","startDateStruct":{"date":"2017-10-19","type":"ACTUAL"},"conditions":["Heavy Menstrual Bleeding","Uterine Fibroid"],"count":477,"armGroups":[{"label":"Relugolix plus E2/NETA","type":"EXPERIMENTAL","interventionNames":["Drug: Relugolix","Drug: Estradiol/norethindrone acetate"]}],"interventions":[{"name":"Relugolix","otherNames":["MVT-601","TAK-385"]},{"name":"Estradiol/norethindrone acetate","otherNames":["E2/NETA"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1\\. Completed 24 weeks of study drug treatment and study participation in either pivotal study, MVT-601-3001 or MVT-601-3002\n\nKey Exclusion Criteria:\n\n1. Has undergone myomectomy, ultrasound-guided laparoscopic radiofrequency ablation, or any other surgical procedure for fibroids, uterine artery embolization, magnetic resonance-guided focused ultrasound for fibroids, or endometrial ablation for abnormal uterine bleeding at any time during the pivotal study (MVT-601-3001 or MVT-601-3002)\n2. Met a withdrawal criterion in the pivotal study (MVT-601-3001 or MVT-601-3002).","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Of Participants Who Achieved Or Maintained An MBL Volume Of <80 Milliliters (mL) And At Least A 50% Reduction From Baseline MBL Volume At Week 52/End Of Treatment","description":"A responder was a participant who had MBL volume of \\< 80 mL and at least a 50% reduction from baseline MBL volume over the last 35 days of treatment (up to Week 52). All returned feminine products collected at each clinical visit were analyzed by the alkaline hematin method to obtain the MBL volume. MBL volume was measured over the Week 52/early termination feminine product collection interval (up to 35 days prior to the last dose of treatment). The percentage of participants who were responders are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.50","spread":null},{"groupId":"OG001","value":"79.87","spread":null},{"groupId":"OG002","value":"75.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Pivotal Study Baseline In MBL Volume At Week 52","description":"MBL volume was measured using the alkaline hematin method, which involves chemically measuring the blood content of used feminine products. The volume of MBL is measured in mL and a blood loss of 80 mL or more per cycle is considered diagnostic of heavy menstrual bleeding. The least squares (LS) mean was derived for each treatment group using a mixed-effects model with repeated measure with visit, region, and Baseline MBL as fixed effects.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-251.6","spread":"16.38"},{"groupId":"OG001","value":"-219.1","spread":"13.91"},{"groupId":"OG002","value":"-204.7","spread":"13.31"}]}]}]},{"type":"SECONDARY","title":"Percentage Of Participants Who Achieved Or Maintained Amenorrhea Over The Last 35 Days Of Treatment","description":"Amenorrhea was defined as meeting 1 of the following criteria for 2 consecutive visits:\n\n* No feminine product returned due to reported amenorrhea;\n* No feminine product returned due to reports of spotting/negligible bleeding coupled with other data (participant's paper diary) indicating infrequent non-cyclic bleeding/spotting; and\n* Feminine product collection with a negligible observed MBL volume coupled with data (participant's paper diary) indicating infrequent non-cyclic bleeding/spotting.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.55","spread":null},{"groupId":"OG001","value":"68.46","spread":null},{"groupId":"OG002","value":"57.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Of Participants With A Hemoglobin Level ≤10.5 Gram/Deciliter (g/dL) At Pivotal Study Baseline Who Achieved An Increase Of >2 g/dL From Pivotal Study Baseline At Week 52","description":"Blood samples were collected from participants for hemoglobin measurements. Percentages are based on number of participants with hemoglobin ≤10.5 g/dL at pivotal study Baseline and reported at Week 52.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.97","spread":null},{"groupId":"OG001","value":"78.95","spread":null},{"groupId":"OG002","value":"42.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number Of Participants With Hemoglobin Increase Of ≥1 g/dL From Pivotal Study Baseline At Week 52 Among Those With A Hemoglobin Concentration Below Lower Limit Of Normal At Pivotal Baseline","description":"Blood samples were collected from participants for hemoglobin measurements. Percentages are based on number of participants with hemoglobin concentration below the lower limit of normal (11.6 g/dL) at pivotal study Baseline and reported at Week 52.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Pivotal Study Baseline In Hemoglobin Concentration At Week 52","description":"Blood samples were collected from participants for hemoglobin measurements. The LS mean was derived for each treatment group using a mixed-effects model with repeated measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"0.24"},{"groupId":"OG001","value":"3.0","spread":"0.23"},{"groupId":"OG002","value":"1.9","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Change From Pivotal Study Baseline In The UFS-QoL Symptom Severity Scale At Week 52","description":"Transformed score ranges from 0 to 100 based on Likert scale (none of time, a little of time, some of the time, most of the time, and all of the time). Lower score indicates less distress and higher score indicates greater distress. A negative change from baseline indicates improvement. The LS mean was derived for each treatment group using a mixed-effects model with repeated measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.3","spread":"2.47"},{"groupId":"OG001","value":"-38.2","spread":"2.77"},{"groupId":"OG002","value":"-35.0","spread":"2.48"}]}]}]},{"type":"SECONDARY","title":"Change From Pivotal Study Baseline In The UFS-QoL Score Health-Related Quality of Life Subscales Score At Week 52","description":"Assessed using the UFS-QoL questionnaire. The UFS-QoL subscale scores include items related to uterine fibroid-associated limitations/impairment in activities, revised activities, concern, energy/mood, control, self-consciousness, and sexual function. The scores were transformed to normalized scores. Transformed score ranges from 0 to 100. Higher scores are indicative of better health-related quality of life (high = good). The LS mean was derived for each treatment group using a mixed-effects model with repeated measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.4","spread":"2.92"},{"groupId":"OG001","value":"56.4","spread":"3.10"},{"groupId":"OG002","value":"51.2","spread":"3.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8","spread":"2.72"},{"groupId":"OG001","value":"46.9","spread":"2.82"},{"groupId":"OG002","value":"45.2","spread":"2.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.2","spread":"2.78"},{"groupId":"OG001","value":"48.0","spread":"2.97"},{"groupId":"OG002","value":"46.9","spread":"2.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","spread":"2.67"},{"groupId":"OG001","value":"38.6","spread":"2.88"},{"groupId":"OG002","value":"36.5","spread":"2.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.0","spread":"2.69"},{"groupId":"OG001","value":"36.4","spread":"2.82"},{"groupId":"OG002","value":"32.2","spread":"2.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":"3.06"},{"groupId":"OG001","value":"35.4","spread":"3.40"},{"groupId":"OG002","value":"31.0","spread":"3.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":"3.40"},{"groupId":"OG001","value":"22.0","spread":"3.87"},{"groupId":"OG002","value":"24.1","spread":"3.62"}]}]}]},{"type":"SECONDARY","title":"Change From Pivotal Study Baseline In The UFS-QoL Score By Health-Related Quality of Life Total Score At Week 52","description":"Assessed using the UFS-QoL Questionnaire. The UFS-QoL total score was the sum of the subscales (concern, activities, revised activities, energy/mood, control, self-conscious, and sexual function). The raw scores were transformed to normalized scores. Transformed score ranges from 0 to 100. Higher scores are indicative of better health-related quality of life (high = good). The LS mean was derived for each treatment group using a mixed-effects model with repeated measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.4","spread":"2.50"},{"groupId":"OG001","value":"41.7","spread":"2.68"},{"groupId":"OG002","value":"39.0","spread":"2.63"}]}]}]},{"type":"SECONDARY","title":"Change From Pivotal Study Baseline In The Uterine Fibroid Symptom Health-Related Quality of Life (UFS-QoL) Bleeding And Pelvic Discomfort (BPD) Scale At Week 52","description":"The BPD scale has been derived from the UFS-QoL symptom severity scale. The scale consists of the following 3 symptoms proximal to uterine fibroids that are experienced by most participants: heavy bleeding during the menstrual period (Question 1), passing blood clots during the menstrual period (Question 2), and feeling tightness or pressure in the pelvic area (Question 5). Raw scores were transformed to a normalized score, with a range of possible scores from 0 to 100 (none of time, a little of time, some of the time, most of the time, and all of the time), where higher scores values are indicative of greater distress and lower scores are indicative of minimal distress. The LS mean was derived for each treatment group using a mixed-effects model with repeated measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-51.3","spread":"2.66"},{"groupId":"OG001","value":"-51.6","spread":"3.11"},{"groupId":"OG002","value":"-48.6","spread":"2.76"}]}]}]},{"type":"SECONDARY","title":"Change From Pivotal Study Baseline In Uterine Volume At Week 52","description":"Volume of the uterus was measured by transvaginal or transabdominal ultrasound. The LS mean was derived for each treatment group using a mixed-effects model with repeated measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-73.31","spread":"14.471"},{"groupId":"OG001","value":"-91.67","spread":"20.143"},{"groupId":"OG002","value":"-37.62","spread":"14.541"}]}]}]},{"type":"SECONDARY","title":"Change From Pivotal Study Baseline In Uterine Fibroid Volume At Week 52","description":"Volume of the primary uterine fibroid was measured by transvaginal or transabdominal ultrasound. The LS mean was derived for each treatment group using a mixed-effects model with repeated measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.84","spread":"5.353"},{"groupId":"OG001","value":"-28.18","spread":"5.523"},{"groupId":"OG002","value":"-17.07","spread":"5.726"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Pivotal Study Baseline In Bone Mineral Density (BMD) At The Lumbar Spine (L1-L4), Femoral Neck, And Total Hip At Week 52","description":"Assessed by dual-energy X-ray absorptiometry (DXA) scan at the lumbar spine (L1-L4), total hip, and femoral neck at pivotal study Baseline and at Week 52. The scans were read by the central radiology laboratory in accordance with the imaging charter. The same DXA machine was used at the local imaging center at each site and operated in the same scan mode for all images procured for an individual participant. All images were submitted for central reading. The central radiology laboratory collected and evaluated all DXA scans for acceptability and measured BMD. The LS mean was derived for each treatment group using a mixed-effects model with repeated measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.804","spread":"0.2803"},{"groupId":"OG001","value":"-2.045","spread":"0.2679"},{"groupId":"OG002","value":"-0.775","spread":"0.2781"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.153","spread":"0.2337"},{"groupId":"OG001","value":"-0.842","spread":"0.2308"},{"groupId":"OG002","value":"-0.065","spread":"0.2086"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.575","spread":"0.3208"},{"groupId":"OG001","value":"-0.513","spread":"0.4503"},{"groupId":"OG002","value":"0.004","spread":"0.3886"}]}]}]},{"type":"SECONDARY","title":"Change From Pivotal Study Baseline In Predose Serum E2 Concentrations At Week 52","description":"Blood samples were collected from participants at predose for E2 measurements. These were analyzed at a central laboratory.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.83","spread":"91.525"},{"groupId":"OG001","value":"-33.77","spread":"106.407"},{"groupId":"OG002","value":"-29.99","spread":"81.465"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Pivotal Study Baseline In European Quality Of Life Five Dimension Five Level (EQ-5D-5L) Scale At Week 52","description":"The EQ-5D-5L scale is a standardized instrument for use as a measure of health outcomes. Mobility, self-care, usual activities, pain/discomfort, and anxiety/depression were each assessed on 5-point categorical scales of no problems to unable to complete specified activity, or no pain/discomfort to extreme pain/discomfort, or not anxious/depressed to extremely anxious/depressed. The change from baseline is summarized by amount of improvement (1-4 categories), amount of deterioration (1-4 categories), or no change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":163},"commonTop":["Headache","Nasopharyngitis","Hot flush","Hypertension"]}}}